Production of recombinant protein therapeutics in cultivated mammalian cells FM Wurm Nature biotechnology 22 (11), 1393-1398, 2004 | 2857 | 2004 |
Transfecting mammalian cells: optimization of critical parameters affecting calcium-phosphate precipitate formation M Jordan, A Schallhorn, FM Wurm Nucleic acids research 24 (4), 596-601, 1996 | 1083 | 1996 |
Designing CD4 immunoadhesins for AIDS therapy DJ Capon, SM Chamow, J Mordenti, SA Marsters, T Gregory, H Mitsuya, ... Nature 337 (6207), 525-531, 1989 | 940 | 1989 |
Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160 PW Berman, TJ Gregory, L Riddle, GR Nakamura, MA Champe, JP Porter, ... Nature 345 (6276), 622-625, 1990 | 807 | 1990 |
Recombinant protein production by large-scale transient gene expression in mammalian cells: state of the art and future perspectives L Baldi, DL Hacker, M Adam, FM Wurm Biotechnology letters 29, 677-684, 2007 | 391 | 2007 |
Transfection of adherent and suspended cells by calcium phosphate M Jordan, F Wurm Methods 33 (2), 136-143, 2004 | 327 | 2004 |
Large-scale transient expression in mammalian cells for recombinant protein production F Wurm, A Bernard Current opinion in biotechnology 10 (2), 156-159, 1999 | 311 | 1999 |
Rational vector design and multi-pathway modulation of HEK 293E cells yield recombinant antibody titers exceeding 1 g/l by transient transfection under serum-free conditions G Backliwal, M Hildinger, S Chenuet, S Wulhfard, M De Jesus, FM Wurm Nucleic acids research 36 (15), e96-e96, 2008 | 288 | 2008 |
High resolution analysis of functional determinants on human tissue-type plasminogen activator. WF Bennett, NF Paoni, BA Keyt, D Botstein, AJ Jones, L Presta, FM Wurm, ... Journal of Biological Chemistry 266 (8), 5191-5201, 1991 | 278 | 1991 |
Biological properties of a CD4 immunoadhesin RA Byrn, J Mordenti, C Lucas, D Smith, SA Marsters, JS Johnson, ... Nature 344 (6267), 667-670, 1990 | 278 | 1990 |
Transient gene expression: recombinant protein production with suspension‐adapted HEK293‐EBNA cells P Meissner, H Pick, A Kulangara, P Chatellard, K Friedrich, FM Wurm Biotechnology and bioengineering 75 (2), 197-203, 2001 | 277 | 2001 |
GFP‐expressing mammalian cells for fast, sensitive, noninvasive cell growth assessment in a kinetic mode L Hunt, M Jordan, M De Jesus, FM Wurm Biotechnology and bioengineering 65 (2), 201-205, 1999 | 270 | 1999 |
Lactate metabolism shift in CHO cell culture: the role of mitochondrial oxidative activity F Zagari, M Jordan, M Stettler, H Broly, FM Wurm New biotechnology 30 (2), 238-245, 2013 | 259 | 2013 |
CD8β Endows CD8 with Efficient Coreceptor Function by Coupling T Cell Receptor/CD3 to Raft-associated CD8/p56lck Complexes A Arcaro, C Grégoire, TR Bakker, L Baldi, M Jordan, L Goffin, ... The Journal of experimental medicine 194 (10), 1485-1495, 2001 | 258 | 2001 |
Serum‐free large‐scale transient transfection of CHO cells M Derouazi, P Girard, F Van Tilborgh, K Iglesias, N Muller, M Bertschinger, ... Biotechnology and bioengineering 87 (4), 537-545, 2004 | 253 | 2004 |
Inducible overproduction of the mouse c-myc protein in mammalian cells. FM Wurm, KA Gwinn, RE Kingston Proceedings of the National Academy of Sciences 83 (15), 5414-5418, 1986 | 248 | 1986 |
Valproic acid: a viable alternative to sodium butyrate for enhancing protein expression in mammalian cell cultures G Backliwal, M Hildinger, I Kuettel, F Delegrange, DL Hacker, FM Wurm Biotechnology and bioengineering 101 (1), 182-189, 2008 | 238 | 2008 |
25 years of recombinant proteins from reactor-grown cells—where do we go from here? DL Hacker, M De Jesus, FM Wurm Biotechnology advances 27 (6), 1023-1027, 2009 | 224 | 2009 |
CHO quasispecies—implications for manufacturing processes FM Wurm Processes 1 (3), 296-311, 2013 | 220 | 2013 |
Development of stable cell lines for production or regulated expression using matrix attachment regions M Zahn-Zabal, M Kobr, PA Girod, M Imhof, P Chatellard, M de Jesus, ... Journal of biotechnology 87 (1), 29-42, 2001 | 220 | 2001 |